Dosing Begins in Trial of Efanesoctocog Alfa in Boys With Severe Hemophilia A

Dosing Begins in Trial of Efanesoctocog Alfa in Boys With Severe Hemophilia A

292018

Dosing Begins in Trial of Efanesoctocog Alfa in Boys With Severe Hemophilia A

A first patient has been dosed in XTEND-Kids, a Phase 3 clinical trial evaluating the safety and efficacy of the investigational replacement therapy efanesoctocog alfa in boys with severe hemophilia A. Hemophilia A is caused by the lack of a functional blood clotting protein called factor VIII (FVIII). Replacement therapies for hemophilia A work by providing patients with the missing FVIII protein. Efanesoctocog alfa, formerly BIVV001, is a potentially longer-lasting replacement therapy for hemophilia A…

You must be logged in to read/download the full post.